header logo image


Page 29«..1020..28293031..4050..»

Archive for the ‘Regenerative Medicine’ Category

Anika Therapeutics Closes Acquisition of Parcus Medical – Yahoo Finance

Sunday, January 26th, 2020

Transaction Accelerates Anikas Revenue Growth, Broadens Joint Preservation and Restoration Product Portfolio, Enhances Commercial Capabilities and Expands Pipeline

BEDFORD, Mass., Jan. 24, 2020 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc.(ANIK), a global, integrated joint preservation and regenerative therapies company with products leveraging its proprietaryhyaluronic acid (HA) technology platform, today announced it has closed its acquisition of Parcus Medical, a leading, privately held sports medicine company.

Under the previously disclosed terms of the agreement, Anika acquired all outstanding membership interests of Parcus Medical in exchange for an upfront payment of approximately$35 millionin cash from the companys existing balance sheet, subject to customary closing adjustments. Parcus Medical unitholders will be eligible to receive an additional$60 millioncontingent upon the achievement of certain commercial milestones.

I want to congratulate our team on closing the Parcus Medical transaction and officially welcome the Parcus Medical team to the Anika family, said Joseph Darling, President and Chief Executive Officer of Anika Therapeutics. This acquisition immediately adds a diverse base of high-growth revenue and will help us achieve the objectives we set forth in our five-year strategic plan. We can now turn our attention to executing our integration plan and continuing to transform Anika into a leading global sports and regenerative medicine company.

Parcus Medical has a diverse product family that helps facilitate surgical procedures on the shoulder, knee, hip and distal extremities. The acquisition significantly expands Anikas offerings into the fast-growing ambulatory surgical center market. The Parcus Medical executive team, led by PresidentMark Brunsvold, will join Anika and continue to lead the Parcus Medical business.

SVB Leerink LLCacted as exclusive financial advisor to Anika andSullivan & Cromwell LLPacted as Anikas legal counsel in connection with the Parcus Medical transaction.

AboutAnika Therapeutics, Inc.Anika Therapeutics, Inc.(ANIK) is a global, integrated joint preservation and regenerative therapies company based inBedford, Mass.Anika is committed to delivering therapies to improve the lives of patients across a continuum of care from osteoarthritis pain management to joint preservation and restoration. The company has more than two decades of global expertise commercializing more than 20 products based on its proprietaryhyaluronic acid (HA) technology platform. For more information about Anika, please visitwww.anikatherapeutics.com.

Forward-Looking StatementsThis press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended, concerning, but not limited to, the acquisition of Parcus Medical and the effects of the acquisition.The Securities and Exchange Commission("SEC") encourages companies to disclose forward-looking statements so that investors can better understand a companys future prospects and make informed investment decisions. Forward-looking statements are subject to risks and uncertainties, many of which are outside our control, which could cause actual results to differ materially from these statements. Therefore, you should not rely on any of these forward-looking statements. Forward-looking statements can be identified by such words as "will," "likely," "may," "believe," "expect," "anticipate," "intend," "seek," "designed," "develop," "would," "future," "can," "could," and other expressions that are predictions of or indicate future events and trends and that do not relate to historical matters. All statements other than statements of historical facts included in this press release regarding our strategies, prospects, financial condition, operations, costs, plans, and objectives are forward-looking statements.

Follow this link:
Anika Therapeutics Closes Acquisition of Parcus Medical - Yahoo Finance

Read More...

Celavie Biosciences Presented Five-Year Follow-Up Data in Parkinsonian Patients at the World Stem Cell Summit – Financialbuzz.com

Sunday, January 26th, 2020

Celavie Biosciences, LLC, a company working to improve lives and restore hope by advancing innovations in CNS diseases with regenerative stem cell-based therapies, today announced their presentation of a poster, titled Five year follow-up on the first-in-human transplantation of undifferentiated stem cells into Parkinsonian patients reveals no adverse effects with improvement in motor function or arrest of the disease progression in five out of seven patients, at the Phacilitate Leaders World and World Stem Cell Summit, held January 21-24 in Miami, Florida.

The poster shows five-year follow-up data that expands on the exploratory clinical data in 7 PD patients with four-year follow-up published in Cell Transplantation in 2018. Oleg Kopyov, Executive Vice President and Chief Scientific Officer at Celavie, presented the poster on-site at the Miami Hyatt Regency.

In the results at one year after cell grafting, all but two of the seven patients completing the study showed various degrees of motor improvement, and five of them showed better response to medication. At five-year evaluation, Unified Parkinsons Disease Rating Scale III (UPDRS III) scores remained better than at baseline in 4/7 patients in the OFF condition and in 5/7 patients in the ON condition. None of the patients showed unwanted motor disturbances (dyskinesias), tumor formation, or any detectable immune responses to the grafted cells.

We are excited that the five-year data for our exploratory clinical trial suggest that the neural progenitor cells are able to stop or slow down the motor deterioration in Parkinsons patients that one would expect to see in this timespan, showing continued improvement even compared to the fourth year, said Oleg Kopyov. We anticipate filing an IND with the FDA for a Phase I U.S. trial in patients with moderate to advanced Parkinsons disease this year.

In addition, Sandy Solmon, Celavies CEO, will deliver presentations at two upcoming international industry conferences:

Ms. Solmon will discuss Celavies application of the companys human undifferentiated allogeneic pluripotent stem cells in Parkinsons disease, as well as pre-clinical data in cerebellar ataxia and upcoming milestones. To schedule a meeting with Celavie Biosciences at these conferences, please contact: Mary Beth Cicero at mbcicero@lavoiehealthscience.com.

About the World Stem Cell Summit

Produced by the non-profit Regenerative Medicine Foundation (RMF), and in its 15th year, the World Stem Cell Summit will take place January 21-24, 2020, in Miami, Florida in partnership with Phacilitate Leaders World, as part of Advanced Therapies Week. The Summit is the most inclusive and expansive interdisciplinary, networking, and partnering meeting in the stem cell science and regenerative medicine field. With the overarching purpose of fostering translation of biomedical research, funding, and investments targeting cures, the Summit and co-located conferences serve a diverse ecosystem of stakeholders. For more information about the upcoming World Stem Cell Summit in Miami, please visit: http://www.worldstemcellsummit.com.

About Celavie Biosciences

Celavie Biosciences is a privately-held company whose mission is to improve lives and restore hope by advancing regenerative stem cell therapies for the treatment of Parkinsons disease and other disorders of the central nervous system (CNS). The company develops undifferentiated, unmodified allogeneic pluripotent stem cell-based therapies, holds a strong IP portfolio, including 18 issued patents, and has an experienced management team blending expertise in concept and cell technology, product scalability and entrepreneurship. Celavet, a subsidiary, applies the same proprietary technologies for the treatment and prevention of serious veterinary diseases. More information is available at https://www.celavie.com/.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200122005497/en/

View original post here:
Celavie Biosciences Presented Five-Year Follow-Up Data in Parkinsonian Patients at the World Stem Cell Summit - Financialbuzz.com

Read More...

FDA cell and gene therapy forecast ‘unlikely’ – Bioprocess Insider – BioProcess Insider

Sunday, January 26th, 2020

Manufacturing issues and a scarcity of new commercial products leave predictions that 10-20 cell and gene therapy approvals each year by 2025 somewhat fanciful, says Dark Horse Consulting.

In his plenary address at the Phacilitate conference yesterday, Anthony Davies, founder of cell and gene therapy specialist firm Dark Horse Consulting, reflected on the difficulties the sector has faced since the high of 2017 when three products achieved US Food and Drug Administration (FDA) approval: Kymriah (tisagenlecleucel) and Yescarta (axicabtagene ciloleucel), and gene therapy Luxturna (voretigene neparvovec).

A few years ago, I introduced this evening by saying: Finally the field has had the year that weve been saying we are going to have for years. That was a great year, he told the packed room in Miami, Florida.

Dark Horses Anthony Davies opened the Phacilitate conference in Miami, Florida

The CAR-T therapies Kymriah and Yescarta gave hope to patients who previously could measure their life expectancy in a small number of months, while gene therapy Luxturna offered hope to children whose ophthalmic deterioration was a statistical certainty, he added.

With these breakthroughs, positivity was high and in January 2019 then FDA Commissioner Scott Gottlieb predicted in an agency statement that there will be upwards of 200 regenerative medicine IND submissions from 2020, and by 2025 the agency will be approving 10 to 20 cell and gene therapy products a year.

I think 200 INDs is doable this year, but INDs do not cure patients, Davies said. And I think if weve struggled with getting three commercial approvals in the years after that first year when three commercial approvals were made, so getting 10-20 in five years from now is going to be extremely challenging.

Since that breakthrough year, the industry has been hot by bad news and a lack of commercial products. Novartis/AveXis Zolgensma (onasemnogene abeparvovec) and bluebirds Zynteglo (autologous CD34+ cells encoding A-T87Q-globin gene) were approved by the FDA last year, while Takedas allogeneic cell therapy Alofisel (darvadstrocel) has been approved to a certain extent in Europe.

While Davies described the approval of Zolgensma, at a cost of $2.1 million, as groundbreaking, he noted it has been overshadowed by a scandal involving data falsification during the approval process.

He also noted that Zynteglos success has been muted by multiple manufacturing problems which has delayed launch.

Meanwhile, pioneer product Kymriah continues to suffer from manufacturing difficulties, and Novartis seems to be struggling with fixing them, Davies suggested.

At JP Morgan [Healthcare Conference] it was announced that for 10% of patients no shipment of drug is made, and for a very significant minority of patients shipment is made with out-of-spec product for which Novartis cannot charge, he told the conference

He added that at the investor conference last week, Novartis CEO Vasant Narasimhan said that they had made great process in identifying the manufacturing issues and were negotiating their resolution with the FDA.

This was exactly the same statement he made at JP Morgan the year before that.

But despite the slowdown in commercialization and industrys challenges, Davies said there remains a lot to be positive about.

Everything that I said reflects the extreme difficulty in bringing this class of therapeutics to market. If these therapeutics were easy to develop,p they would have been developed. If diseases were easy to cure, we wouldnt need new therapeutics.

Let us just use these good pieces of news and these bad pieces of news as inspiration, lets continually remind ourselves that what we do is one of the hardest things in science or medicine at this time.

Davies was not alone in his views.

Speaking Wednesday, Robert Preti, CEO of Hitachi Chem Advanced Therapeutic Solutions, admitted the industry is behind where he thought it would be when he began his career 37 years ago, but said he was not too worried.

I want to commend this industry on what we have achieved for patients, he said, noting the difficulty in developing and making these therapies. He also highlighted that with over 1,000 regenerative therapies in development, problems will eventually be ironed out and cell and gene therapies will make the widespread impact intended.

More here:
FDA cell and gene therapy forecast 'unlikely' - Bioprocess Insider - BioProcess Insider

Read More...

Regenerative Medicine Market Market 2020 | Trends, Segmentation, Applications and Opportunities Forecasts To 2027 – VOICE of Wisconsin Rapids

Sunday, January 26th, 2020

Regenerative Medicine report is a comprehensive analysis of global market has newly added by Healthcare Intelligence Markets to its extensive repository. The statistical report offers a prime wellspring of applicable information for global business progress.

Regenerative Medicine research reports growth rates and market value based on market dynamics, growth factors. Complete knowledge is based on the latest innovations in the industry, opportunities and trends. In addition to SWOT analysis by key suppliers, the report contains a comprehensive market analysis and major players landscape.

Ask for Sample Copy of This Report: https://www.healthcareintelligencemarkets.com/request_sample.php?id=135675

Top Key Players Profiled in This Report: DePuy SynthesMedtronicZimmerBiometStrykerAcelityMiMedx GroupOrganogenesisUniQureCellular Dynamics InternationalOsiris TherapeuticsVcanbioGamida CellGolden MeditechCytoriCelgeneVericel CorporationGuanhao BiotechMesoblastStemcell TechnologiesBellicum Pharmaceuticals

The key questions answered in the report:

1. What will be the market size and growth rate in the forecast year?

2. What are the key factors driving the Regenerative Medicine?

3. What are the risks and challenges in front of the market?

4. Who are the key vendors in the Regenerative Medicine?

5. What are the trending factors influencing the market shares?

6. What are the key outcomes of Porters five forces model?

7. Which are the global opportunities for expanding the Regenerative Medicine?

The purpose of this study is to define the overview of the Regenerative Medicine with respect to market size, shares, sales patterns, and pricing structures. Primary and secondary research refer collect the desired data of the target market. Different global regions such as North America, Latin America, Asia-Pacific, Africa, and the Middle East are examined to evaluate the facts about productivity.

Get Discount on This Report: https://www.healthcareintelligencemarkets.com/ask_for_discount.php?id=135675

Reasons for buying this research report:

Identification of key factors instrumental in changing the Regenerative Medicine scenario, exploiting new opportunities, and gaining competitive edge.

Analyzing various perspectives of the market with the help of Porters five forces analysis.

End-user industry that is likely to witness highest adoption of these Regenerative Medicine.

Regions that are expected to witness the fastest growth during the forecast period.

Finally, researchers throw light on pinpoint analysis of Regenerative Medicine dynamics. It also measures the sustainable trends and platforms which are the basic roots behind the market growth. The degree of competition is also measured in the research report. With the help of SWOT and Porters five analysis, the market has been deeply analyzed. It also helps to address the risk and challenges in front of the businesses. Furthermore, it offers extensive research on sales approaches.

If You Have Any Query, Ask Our Experts: https://www.healthcareintelligencemarkets.com/enquiry_before_buying.php?id=135675

Table of Contents:

Chapter 1: Regenerative Medicine OverviewChapter 2: Global Economic Impact on IndustryChapter 3: Market Competition by ManufacturersChapter 4: Production, Revenue (Value) by RegionChapter 5: Supply (Production), Consumption, Export, Import by RegionsChapter 6: Production, Revenue (Value), Price Trend by TypeChapter 7: Regenerative Medicine Analysis by ApplicationChapter 8: Manufacturing Cost AnalysisChapter 9: Industrial Chain, Sourcing Strategy and Downstream BuyersChapter 10: Marketing Strategy Analysis, Distributors/TradersChapter 11: Market Effect Factors AnalysisChapter 12: Regenerative Medicine Forecast

Marvella Lit

View all posts byMarvella Lit

Excerpt from:
Regenerative Medicine Market Market 2020 | Trends, Segmentation, Applications and Opportunities Forecasts To 2027 - VOICE of Wisconsin Rapids

Read More...

Why stem cells could be the medical innovation of the century – World Economic Forum

Tuesday, January 21st, 2020

Right now, your bodys stem cells are working hard replacing your skin every two weeks, creating new red and white blood cells and completing thousands of other tasks essential to life. They are your own personalized fountain of youth.

Scientists generally agree that a stem cell should be able to do both of the following:

One theory of ageing suggests that between the ages of 30 and 50, our stem cells reach a turning point and start to decline in number and function. This results in the typical features associated with ageing.

There does not seem to be a single discoverer of stem cells. Accounts date back to the 1800s and even further, but the first successful medical procedure was a bone marrow transfusion in 1939. Advances in immunology led to donor matching, initially via siblings and close relatives. Unrelated donor matching flourished in the 1970s, alongside donor registries.

In the 1980s, scientists identified embryonic stem cells in mice, leading to the 1997 cloning of Dolly the Sheep. This created immense interest for human and medical applications and a backlash in the US as federal R&D funding was essentially halted in 2001.

In 2012, a Nobel Prize was awarded for the earlier discovery of induced pluripotent stem cells (iPS). Essentially, they return potency and self-renewal properties to mature non-stem cells, essentially making them act like stem cells again.

In the decade between 2010 and 2019, the first wave of stem cell start-ups emerged, alongside R&D programmes at many large pharmaceutical companies, leading to innovation and the first human clinical trials for iPS and other related therapies.

According to Q3 2019 data from the Alliance for Regenerative Medicine, there are 959 regenerative medicine companies worldwide sponsoring 1,052 active clinical trials; 525 of these companies are in North America, 233 in Europe and Israel, and 166 in Asia. In aggregate, $7.4 billion has been invested in regenerative medicine companies in 2019; $5.6 billion of which has been dedicated to gene and gene-modified cell therapy, $3.3 billion in cell therapy, and $114 million in tissue engineering.

Overview of the cancer stem cells market

Perhaps most excitingly, curative therapies are hitting the market and the results are astonishing: 60% of Acute Lymphoblastic Leukemia patients taking Novartis Kymirah showed a complete response (no traces of cancer) and were declared in full remission. Meanwhile, 75% of patients with Transfusion-Dependent -Thalassaemia treated with bluebird bios Zynteglo achieved independence from transfusions. Perhaps most astonishingly, 93% of spinal muscular atrophy patients treated with Novartis Zolgensma were alive without permanent ventilation 24 months after treatment. We should expect more medical breakthroughs in the coming years.

New science, new start-ups: several companies in the sector have gone public or been acquired. These exits led to the recycling of talent and capital into new companies. Because the science and commercial systems have also advanced, the companies in the next wave are pursuing bigger challenges, driving innovation, with even greater resources.

Patients are eager: the current market for stem cell therapies is growing at 36% per year, though it will rapidly expand when a breakthrough occurs toward the treatment of a non-communicable disease (such as cancer, diabetes, heart disease) or a lifestyle factor (for example, growing hair in the correct places, expanding cognitive abilities or increasing healthy lifespan).

New R&D models: funding is flowing into the sector from large companies, VC funds, and institutions such as the California Institute for Regenerative Medicine (CIRM) and New York State Stem Cell Science programme (NYSTEM). Some of the leading university R&D platforms include the Center for the Commercialization of Regenerative Medicine in Toronto, the Stanford Institute for Stem Cell Biology and Regenerative Medicine, the Oxford Stem Cell Institute, and most notably, the Harvard Stem Cell Institute (HSCI).

Founded in 2004, HSCI has established a phenomenal track record. It provided the first $200,000 in funding to Derrick Rossis lab, which inspired the largest biotech IPO to date. HSCI scientists were also co-founders or principals in the three most prominent gene-editing companies (CRISPR Tx, Intellia and Editas), the combined $1.55-billion True North/iPierian acquisitions and the recent $950-million acquisition of Semma Tx, Frequency Tx, Fate Tx, Epizyme Inc., and Magenta Tx.

For the casual investor, Evercore ISI is building a Regenerative Medicine Index, which may be the simplest way to build a portfolio. For institutions and those with deeper pockets, regenerative medicine funds are forming, including the Boston-centric Hexagon Regenerative Medicine Fund, which aims to create companies out of the Harvard Stem Cell Institute.

Caveat emptor. Though patients needs are immediate, those seeking treatments should think very carefully about the risks. There are many dubious clinics touting expensive stem cell treatments and some patients have experienced horrifying complications. Dr. Paul Knoepfler of UC-Davis has written a practical and scientifically accurate guide, a strongly recommended read if you or a family member are considering treatment or a clinical trial.

The leading causes of death in 1900 were mostly infectious/communicable diseases. While the prevalence of most causes has diminished, the largest increases include heart disease (+40%) and cancer (+300%). Granted, this is partly due to doubling life expectancy and a lack of death from other causes. However, given time and resources, scientists and physicians may cure these challenging diseases.

Total disease burden by disease or injury

Today, six of the seven leading causes of death are non-communicable diseases (heart disease, stroke, lung diseases, cancer, Alzheimers disease and diabetes). Based on the early promise mentioned above, regenerative medicine may be our best hope to solve the great non-communicable diseases of our time, and perhaps the single most transformative medical innovation in a century.

License and Republishing

World Economic Forum articles may be republished in accordance with our Terms of Use.

The views expressed in this article are those of the author alone and not the World Economic Forum.

Excerpt from:
Why stem cells could be the medical innovation of the century - World Economic Forum

Read More...

Abeona Therapeutics Announces Participation in Inaugural World Congress on Epidermolysis Bullosa – Yahoo Finance

Tuesday, January 21st, 2020

NEW YORK and CLEVELAND, Jan. 21, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (ABEO), a fully-integrated leader in gene and cell therapy, today announced its participation in the first World Congress on Epidermolysis Bullosa (EB2020), which is convening the worlds leading experts on epidermolysis bullosa (EB) research and clinical management in London, January 19-23, 2020. Organized by The Global EB Alliance, EB2020 is a forum to share state-of-the art knowledge on this devastating disease and to debate the direction of future research.

Dr. Jean Tang of Stanford University Medical Center will present updated recessive dystrophic epidermolysis bullosa (RDEB) natural history data on large wounds and highlights from a completed Phase I/II clinical trial of Abeonas investigational EB-101 gene therapy for RDEB. The presentation is part of the Clinical Trials and Research Program track at the congress. Details of the presentation are as follows:Large wounds: an update on natural history data and EB-101Jean Tang, M.D., Ph.D.Professor of Dermatology, Stanford University Medical Center Tuesday, January 2114:25 GMT

About Recessive Dystrophic Epidermolysis BullosaRecessive dystrophic epidermolysis bullosa (RDEB) is a rare connective tissue disorder characterized by severe skin wounds that cause pain and can lead to systemic complications impacting the length and quality of life. People with RDEB have a defect in the COL7A1 gene, leaving them unable to produce functioning Type VII collagen which is necessary to anchor the dermal and epidermal layers of the skin. There is currently no approved treatment for RDEB.

About EB-101EB-101 is an autologous, gene-corrected cell therapy in late-stage clinical development for the treatment of recessive dystrophic epidermolysis bullosa (RDEB), a rare connective tissue disorder without an approved therapy. Treatment with EB-101 involves gene transfer to deliver COL7A1 genes into a patients own skin cells (keratinocytes) and transplanting them back to the patient to enable normal Type VII collagen expression and facilitate wound healing. Data from a Phase I/IIa clinical trial conducted by Stanford University evaluating EB-101 showed that the gene-corrected cell therapy provided durable wound healing for RDEB patients lasting several 2+ to 5+ years, including for the largest, most challenging wounds that affect the majority of the RDEB population. In the U.S., Abeona holds Regenerative Medicine Advanced Therapy, Breakthrough Therapy, and Rare Pediatric designations for EB-101 and Orphan Drug designation in both the U.S. and EU.

About Abeona Therapeutics Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing gene and cell therapies for serious diseases. The Companys clinical programs include EB-101, its autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa, as well as ABO-102 and ABO-101, novel AAV9-based gene therapies for Sanfilippo syndrome types A and B (MPS IIIA and MPS IIIB), respectively. The Companys portfolio of AAV9-based gene therapies also features ABO-202 and ABO-201 for CLN1 disease and CLN3 disease, respectively. Abeona has received numerous regulatory designations from the FDA and EMA for its pipeline candidates, including Regenerative Medicine Advanced Therapy designation for two candidates (EB-101 and ABO-102). http://www.abeonatherapeutics.com

Forward Looking StatementThis press release contains certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties. These statements include statements regarding our pipeline including the potential use of investigational product EB-101 in the treatment of recessive dystrophic epidermolysis bullosa (RDEB). We have attempted to identify forward-looking statements by such terminology as may, will, anticipate, believe, estimate, expect, intend, and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances), which constitute and are intended to identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, numerous risks and uncertainties, including but not limited to continued interest in our rare disease portfolio, our ability to enroll patients in clinical trials, the impact of competition, the ability to secure licenses for any technology that may be necessary to commercialize our products, the ability to achieve or obtain necessary regulatory approvals, the risk of whether or when the Company will complete its Phase 3 clinical trial for EB-101 and any potential results thereof, the impact of changes in the financial markets and global economic conditions, risks associated with data analysis and reporting, and other risks as maybe detailed from time to time in the Companys Annual Reports on Form 10-K and quarterly reports on Form 10-Q and other reports filed by the Company with the Securities and Exchange Commission. The Company undertakes no obligation to revise the forward-looking statements or to update them to reflect events or circumstances occurring after the date of this presentation, whether as a result of new information, future developments or otherwise, except as required by the federal securities laws.

Story continues

See the rest here:
Abeona Therapeutics Announces Participation in Inaugural World Congress on Epidermolysis Bullosa - Yahoo Finance

Read More...

Collaboration to Accelerate Breakthroughs in Regenerative Medicine – 3D Printing Progress

Tuesday, January 21st, 2020

Today, 3D Systems and CollPlant Biotechnologies announced signing a joint development agreement intended to play a pivotal role in advancing and accelerating breakthroughs in the biomedical industry. The collaboration brings together two industry pioneers--3D Systems, renowned for its 3D printing technologies and healthcare expertise; and CollPlant, the developer of proprietary recombinant human collagen (rhCollagen) BioInk technology currently used for 3D bioprinting of tissues and organs. The two companies plan to jointly develop tissue and scaffold bioprinting processes for third party collaborators. For more information see the IDTechEx report on 3D Bioprinting 2018 - 2028: Technologies, Markets, Forecasts.

3D Systems and CollPlant recognized an unmet market need for a comprehensive solution to produce tissues and scaffolds for regenerative medicine applications. The companies intend to create integrated 3D bioprinting solutions comprised of state-of-the-art 3D bioprinters and BioInks to produce tissues and scaffolds. In accordance with the collaboration agreement, both companies may use a combination of 3D Systems' printers, CollPlant's BioInks, and new formulations of rhCollagen-based BioInks jointly developed by the companies, for their own products, as well as for deployments with third parties.

"3D Systems is excited to work with CollPlant to develop groundbreaking bioprinted tissue and scaffold technologies," said Chuck Hull, co-founder and chief technology officer, 3D Systems. "We believe 3D printing to be a key technology for regenerative medicine, and this collaboration is one of many we are entering to play an integral role in this exciting field. Combining our innovative 3D printing technologies with CollPlant's rhCollagen based BioInks has the potential to make a significant impact in bioprinting and regenerative medicine."

"We strongly believe that our proven rhCollagen is the finest building block for regenerative medicine tissues and scaffolds available today," Yehiel Tal, chief executive officer of CollPlant, stated. "As the leading additive manufacturing printing solutions company, 3D Systems is the perfect partner for us. Together, we can offer the best combined technology for 3D bioprinting. We are honored to have established this important collaboration and we look forward to working together to advance 3D bioprinting technology to the commercial phase."

Source and top image: Collplant

The rest is here:
Collaboration to Accelerate Breakthroughs in Regenerative Medicine - 3D Printing Progress

Read More...

Regenerative Medicine Adoption of Innovative Offerings and Forecast 2019-2026 – Melanian News

Tuesday, January 21st, 2020

Global Liver Biopsy System Market Research Report 2019-2025 states that the Liver Biopsy System market has been raising and impacting the international economy in terms of growth rate, revenue, sale, market share, and size. The global market has been over-looking changes in its industry. The report provides the reader with a study fundamental attributes of the industry covering lucrative business strategies, market demands, leading players of the market, and futuristic perspective through various angles for 2019 to 2025 forecast time period. It covers the current situations of the market to represent an outlook of the market to businesses to boost their profitable strategies. The report offers an expert review and detail investigation of fragments of the market using which clients can use for their business favorable position

The market report figures out the growth patterns of organization, areas and type or application from 2019 to 2025. It throws light on the most trending facts of the Liver Biopsy System market, most prominent market, the maximum revenue, manufacture analysis, market share, market size, market forecast trends, market sales, production, supply, and demand. Prominent players are evaluated on the basis of their gross margin, price, sales, revenue, business, products, and other company details.

DOWNLOAD FREE SAMPLE REPORT: https://www.marketresearchplace.com/report-detail/182828/request-sample

The well-established players in the market along with capacity, production, ex-factory price, revenue and market share are covered including: BD, Boston Scientific, Cook Medical, Argon Medical Devices, RI.MOS, Sterylab, Veran Medical, Medtronic, INRAD Inc,

The key regions are extensively analyzed with respect to every parameter of the geographies in question, comprising, North America (United States, Canada, Mexico), Europe (Germany, France, UK, Italy, Russia), Asia-Pacific (China, Japan, South Korea, India, Australia, Indonesia, Thailand, Malaysia, Philippines, Vietnam), Central & South America (Brazil), Middle East & Africa (Turkey, GCC Countries, Egypt, South Africa).

Market segment by type, the product can be split into Percutaneous, Transjugular, Laparoscopic, Transgastric,

Market segment by application, split into: Hospitals, Clinics, Diagnostic Labs, Other,

Drivers & Hindrances of the Liver Biopsy System market: How does the report explicate on the same:

ACCESS FULL REPORT: https://www.marketresearchplace.com/report/global-liver-biopsy-system-market-research-report-2019-2025-182828.html

Moreover The Report Offer:

The report covers an overview of revenue, demand, and supply of data, futuristic cost, and growth analysis during the projected year. In a represented strategy, the authors have used, the correct figures and the graphical depiction. The report states that capabilities and development have boosted the number of huge business models and organizations across the globe. Additionally, comprehensive data about the product consumption across different sections as well as the valuation developed by these regions is also explained in the Liver Biopsy System market report.

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team ([emailprotected]), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

See original here:
Regenerative Medicine Adoption of Innovative Offerings and Forecast 2019-2026 - Melanian News

Read More...

Zika Virus’ Key into Brain Cells ID’d, Leveraged to Block Infection and Kill Cancer Cells – UC San Diego Health

Tuesday, January 21st, 2020

Zika virus infection can stunt neonatal brain development, a condition known as microcephaly, in which babies are born with abnormally small heads. To determine how best to prevent and treat the viral infection, scientists first need to understand how the pathogen gets inside brain cells.

Employing different approaches to answer different questions, two research teams at University of California San Diego School of Medicine independently identified the same molecule v5 integrin as Zika virus key to entering brain stem cells.

In a pair of papers published January 16, 2020 by Cell Press, the researchers also found ways to take advantage of the integrin to both block Zika virus from infecting cells and turn it into something good: a way to shrink brain cancer stem cells.

Integrins are molecules embedded in cell surfaces. They play important roles in cell adherence and communication, and are known to be involved in cancer progression and metastasis. Several other integrins are known entry points for other viruses, including adenovirus, foot-and-mouth disease virus and rotavirus, but v5 was not previously known for its role in viral infections.

One team, led by Tariq Rana, PhD, professor and chief of the Division of Genetics in the Department of Pediatrics at UC San Diego School of Medicine and Moores Cancer Center, used CRISPR gene editing to systematically delete every gene in a 3D culture of human glioblastoma (brain cancer) stem cells growing in a laboratory dish. Then they exposed each variation to Zika virus to determine which genes, and the proteins they encode, are required for the virus to enter the cells. The virus was for the first time labeled with green fluorescent protein (GFP) to allow the researchers to visualize viral entry into the cells.

3D human brain organoids. Left: normal, uninfected. Center: infected with Zika virus. Right: infected with Zika virus and treated with cilengitide, which protects the cells from destruction by the virus.

Their study, published in Cell Reports, uncovered 92 specific human brain cancer stem cell genes that Zika virus requires to infect and replicate in the cells. But one gene stood out, the one that encodes v5 integrin.

Integrins are well known as molecules that many different viruses use as doorknobs to gain entry into human cells, Rana said. I was expecting to find Zika using multiple integrins, or other cell surface molecules also used by other viruses. But instead we found Zika uses v5, which is unique. When we further examined v5 expression in brain, it made perfect sense because v5 is the only integrin member enriched in neural stem cells, which Zika preferentially infects. Therefore, we believe that v5 is the key contributor to Zikas ability to infect brain cells.

The second study, published in Cell Stem Cell, was led by Jeremy Rich, MD, professor in the Department of Medicine at UC San Diego School of Medicine and director of neuro-oncology and of the Brain Tumor Institute at UC San Diego Health. Knowing that many viruses use integrins for entry into human cells, Richs team inhibited each integrin with a different antibody to see which would have the greatest effect.

When we blocked other integrins, there was no difference. You might as well be putting water on a cell, said Rich, who is also a faculty member in the Sanford Consortium for Regenerative Medicine and Sanford Stem Cell Clinical Center at UC San Diego Health. But with v5, blocking it with an antibody almost completely blocked the ability of the virus to infect brain cancer stem cells and normal brain stem cells.

Richs team followed up by inhibiting v5 in a glioblastoma mouse model with either an antibody or by deactivating the gene that encodes it. Both approaches blocked Zika virus infection and allowed the treated mice to live longer than untreated mice. They also found that blocking the v5 integrin in glioblastoma tumor samples removed from patients during surgery blocked Zika virus infection.

Ranas team also blocked v5 in mice, treating them daily with cilengitide or SB273005, two experimental cancer drugs that target the integrin. Six days after Zika virus infection, the brains of their drug-treated mice contained half as much virus as mock-treated mice.

The neat thing is that these findings not only help advance the Zika virus research field, but also opens the possibility that we could similarly block the entry of multiple viruses that use other integrins with antibodies or small molecule inhibitors, Rana said.

Rana and team are now engineering a mouse model that lacks v5 integrin in the brain a tool that would allow them to definitively prove the molecule is necessary for Zika viral entry and replication.

Rich is a neuro-oncologist who specializes in diagnosing and treating patients with glioblastoma, a particularly aggressive and deadly type of brain tumor. When he first saw how the Zika virus shrinks brain tissue, it reminded him of what he hopes to achieve when hes treating a patient with glioblastoma. In 2017, he and collaborators published a study in which they determined that Zika virus selectively targets and kills glioblastoma stem cells, which tend to be resistant to standard treatments and are a big reason why glioblastomas recur after surgery and result in shorter patient survival rates.

Richs latest study helps account for the virus preference for glioblastoma stem cells over healthy brain cells. The v5 integrin is made up of two separate subunits v and 5. The team found that glioblastoma stem cells produce a lot of both the v subunit (associated with stem cells) and 5 subunit (associated with cancer cells). Together, these units form the v5 integrin, which, the team discovered, plays an important role in glioblastoma stem cell survival. Those high levels of v5 integrin also help explain why, in the study, glioblastoma stem cells were killed by Zika virus at much higher rates than normal stem cells or other brain cell types.

It turns out that the very thing that helps cancer cells become aggressive cancer stem cells is the same thing Zika virus uses to infect our cells, Rich said.

To see how this might play out in a more realistic model of human disease, Richs team partnered with an expert in human brain disease modeling Alysson Muotri, PhD, professor at UC San Diego School of Medicine, director of the UC San Diego Stem Cell Program and a member of the Sanford Consortium for Regenerative Medicine, and team. Pinar Mesci, PhD, a postdoctoral researcher in Muotris lab, generated a new brain tumor model, where human glioblastoma tumors were transplanted into human brain organoids, laboratory mini-brains that can be used for drug discovery. The researchers discovered that Zika virus selectively eliminates glioblastoma stem cells from the brain organoids. Inhibiting v5 integrin reversed that anti-cancer activity, further underscoring the molecules crucial role in Zika virus ability to destroy cells.

Now Richs team is partnering with other research groups to perform targeted drug studies. In addition to searching for drugs to block Zika virus, as Ranas group is doing, Rich is interested in genetic modifications to the virus that could help better target its destruction to brain cancer cells, while leaving healthy cells alone.

While we would likely need to modify the normal Zika virus to make it safer to treat brain tumors, we may also be able to take advantage of the mechanisms the virus uses to destroy cells to improve the way we treat glioblastoma, Rich said. We should pay attention to viruses. They have evolved over many years to be very good at targeting and entering specific cells in the body.

Zika virus was perhaps best known in 2015-16, when a large outbreak affected primarily Latin America, but also several other regions of the world. While that particular epidemic has passed, Zika virus has not gone away. Smaller, local outbreaks continue and this past summer, the first few cases of native Zika virus infection were recorded in Europe. Scientists warn Zika could continue to spread as climate change affects the habitat range of the mosquito that carries it. The virus can also be transmitted from pregnant mother to fetus, and via sexual contact. More than half of all people on Earth are at risk for Zika virus infection, and there is no safe and effective treatment or vaccine.

Co-authors of Ranas study, published January 16, 2020 in Cell Reports, include: Shaobo Wang, Qiong Zhang, Shashi Kant Tiwari, Gianluigi Lichinchi, Edwin H. Yau, Hui Hui, Wanyu Li, UC San Diego; and Frank Furnari, UC San Diego and Ludwig Institute for Cancer Research.

This research was funded, in part, by the National Institutes of Health (grants AI125103, CA177322, DA039562, DA046171 and DA049524).

Co-authors of Richs study, published January 16, 2020 in Cell Stem Cell, also include: Zhe Zhu, Jean A. Bernatchez, Xiuxing Wang, Hiromi I. Wettersten, Sungjun Beck, Alex E. Clark, Qiulian Wu, Sara M. Weis, Priscilla D. Negraes, Cleber A. Trujillo, Jair L. Siqueira-Neto, David A. Cheresh, UC San Diego; Ryan C. Gimple, Leo J.Y. Kim, UC San Diego and Case Western Reserve University; Simon T. Schafer, Fred H. Gage, Salk Institute for Biological Studies; Briana C. Prager, UC San Diego, Case Western Reserve University and Cleveland Clinic; Rekha Dhanwani, Sonia Sharma, La Jolla Institute for Allergy and Immunology; Alexandra Garancher, Robert J. Wechsler-Reya, Sanford Burnham Prebys Medical Discovery Institute; Stephen C. Mack, Baylor College of Medicine, Texas Childrens Hospital; Luiz O. Penalva, Childrens Cancer Research Institute; Jing Feng, Zhou Lan, Rong Zhang, Alex W. Wessel, Michael S. Diamond, Hongzhen Hu, Washington University School of Medicine; Sanjay Dhawan, and Clark C. Chen, University of Minnesota.

The research was funded, in part, by the National Institutes of Health (grants CA217065, CA217066, CA203101, CA159859, CA199376, NS097649-01, CA240953-01, NS096368, R01DK103901,R01AA027065, MH107367, N5105969, CA045726, CA050286, CA197718, CA154130, CA169117, CA171652, NS087913, NS089272), California Institute for Regenerative Medicine (CIRM, grants FA1-00607, DISC209649) and International Rett Syndrome Foundation.

Disclosures: Tariq Rana is a co-founder of, member of the scientific advisory board for, and has equity interest in ViRx Pharmaceuticals. Alysson Muotri is a co-founder and has equity interest in TISMOO, a company dedicated to genetic analysis focusing on therapeutic applications customized for autism spectrum disorder and other neurological disorders. David Cheresh is a co-founder of TargeGen and AlphaBeta Therapeutics, a new but currently unfunded company developing an antibody to integrin v5 involved in cancer treatment. The terms of these arrangements have been reviewed and approved by UC San Diego in accordance with its conflict of interest policies. In addition, Michael Diamond, of Washington University School of Medicine, is a consultant for Inbios and Atreca and serves on the Scientific Advisory Board of Moderna.

Follow this link:
Zika Virus' Key into Brain Cells ID'd, Leveraged to Block Infection and Kill Cancer Cells - UC San Diego Health

Read More...

Contract Research Organization (CRO) Market Outlook to 2024 – Increased Technology Adoption in the Form of eClinical Solutions & Innovative Trial…

Tuesday, January 21st, 2020

DUBLIN, Jan. 20, 2020 /PRNewswire/ -- The "Global Contract Research Organization (CRO) Market, Forecast to 2024" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

Owing to a constantly changing pharmaceutical landscape, the industry is expected to witness a moderate 4% to 5% growth in the next 5 to 7 years, to surpass $1.5 trillion by 2025.

Increased technology adoption in the form of eClinical solutions and innovative trial designs is expected to transform the CRO landscape.

In coordination with the industry growth, market participants are investing about 8% to 10% of their revenues toward drug discovery and development. With an overall R&D investment of approximately $170 billion in 2018, the industry is working toward developing new and innovative curative therapies (e.g., regenerative medicine).

As a result of a higher R&D activity, there is higher reliance on outsourcing partners (e.g., CRO vendors) that support pharma and biotech participants with cost-effective and time-efficient drug development services. The global CRO industry is a highly fragmented and competitive market, with more than 1,000 participants globally.

Europe is emerging as a key location for clinical research, with several small-to-mid segment niche CROs focusing on the region and, hence, propelling growth. Moreover, with APAC providing cheaper but effective alternatives for drug development, several big pharma companies are collaborating with participants in the region, thereby, making it the strongest growing region across the CRO industry.

A highly fragmented market is a result of numerous small-to-mid segment participants focused on either a specific therapy area or specific service segment. This, in turn, is propelling consolidation in the industry, with leading CROs acquiring these niche participants, thus, increasing their service portfolio and geographic span.

The global CRO market is also witnessing an increased adoption of digitization in the form of eClinical solutions, using AI and machine learning-based platforms, providing an opportunity for several CROs to position themselves in the segment. Several technology-focused CROs are now developing in-house expertise which is changing the global clinical trial paradigm with the implementation of adaptive, virtual, and remote clinical trials. The companies are also moving toward an embedded business model by integrating their services with that of the sponsor's business strategy, thereby, supporting as an end-to-end solution provider.

Key Issues Addressed

Key Topics Covered

1. Executive Summary

2. Total CRO Market - Overview

3. Drivers, Restraints, and Trends - Total CRO Market

4. Total CRO Market - Forecasts and Trends

5. Discovery and Preclinical CRO Market Analysis

6. Clinical CRO Market Analysis

7. Regional Forecast Analysis - North America

8. Regional Forecast Analysis - Europe

9. Regional Forecast Analysis - Asia-Pacific

10. Regional Forecast Analysis - Rest of World

11. Total CRO Market - Competitive Environment

12. Clinical CRO Subsegment Analysis

13. Bioanalytical and cGMP Testing Subsegment

14. Subsegment Analysis - Central Laboratory Services

15. Subsegment Analysis - Biostatistics

16. Subsegment Analysis - Data Management

17. Subsegment Analysis - Pharmacovigilance

Story continues

18. Subsegment Analysis - Health Economics Outcomes Research (HEOR)

19. Digital Disruption in the CRO Industry

20. Visioning Scenarios

21. CRO Industry Stakeholder Landscape

22. The Last Word

For more information about this report visit https://www.researchandmarkets.com/r/frjl4a

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/contract-research-organization-cro-market-outlook-to-2024---increased-technology-adoption-in-the-form-of-eclinical-solutions--innovative-trial-designs-expected-to-transform-the-cro-landscape-300989712.html

SOURCE Research and Markets

View post:
Contract Research Organization (CRO) Market Outlook to 2024 - Increased Technology Adoption in the Form of eClinical Solutions & Innovative Trial...

Read More...

Those Who Purchased China Regenerative Medicine International (HKG:8158) Shares Three Years Ago Have A 95% Loss To Show For It – Simply Wall St

Tuesday, January 21st, 2020

It is a pleasure to report that the China Regenerative Medicine International Limited (HKG:8158) is up 129% in the last quarter. But that is meagre solace in the face of the shocking decline over three years. The share price has sunk like a leaky ship, down 95% in that time. So it sure is nice to see a big of an improvement. But the more important question is whether the underlying business can justify a higher price still.

We really feel for shareholders in this scenario. Its a good reminder of the importance of diversification, and its worth keeping in mind theres more to life than money, anyway.

View our latest analysis for China Regenerative Medicine International

Because China Regenerative Medicine International made a loss in the last twelve months, we think the market is probably more focussed on revenue and revenue growth, at least for now. Shareholders of unprofitable companies usually expect strong revenue growth. Thats because fast revenue growth can be easily extrapolated to forecast profits, often of considerable size.

Over the last three years, China Regenerative Medicine Internationals revenue dropped 26% per year. Thats definitely a weaker result than most pre-profit companies report. And as you might expect the share price has been weak too, dropping at a rate of 64% per year. Never forget that loss making companies with falling revenue can and do cause losses for everyday investors. Its worth remembering that investors call buying a steeply falling share price catching a falling knife because it is a dangerous pass time.

The companys revenue and earnings (over time) are depicted in the image below (click to see the exact numbers).

Its good to see that there was some significant insider buying in the last three months. Thats a positive. On the other hand, we think the revenue and earnings trends are much more meaningful measures of the business. Dive deeper into the earnings by checking this interactive graph of China Regenerative Medicine Internationals earnings, revenue and cash flow.

China Regenerative Medicine International shareholders are down 81% for the year, but the market itself is up 9.4%. Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. Unfortunately, last years performance may indicate unresolved challenges, given that it was worse than the annualised loss of 45% over the last half decade. Generally speaking long term share price weakness can be a bad sign, though contrarian investors might want to research the stock in hope of a turnaround. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Like risks, for instance. Every company has them, and weve spotted 5 warning signs for China Regenerative Medicine International (of which 1 shouldnt be ignored!) you should know about.

China Regenerative Medicine International is not the only stock that insiders are buying. For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on HK exchanges.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.

Read more from the original source:
Those Who Purchased China Regenerative Medicine International (HKG:8158) Shares Three Years Ago Have A 95% Loss To Show For It - Simply Wall St

Read More...

UK biotech PhoreMost to work with Otsuka on gene therapy projects – – pharmaphorum

Tuesday, January 21st, 2020

Building on an R&D tie-up with an Indian stem cell institution last year, UK biotech PhoreMost has begun a collaboration with Japans Otsuka working on several gene therapy projects.

Cambridge-based PhoreMost said it will use its next-generation phenotypic screening platform Siteseeker to identify novel targets for Otsukas therapeutics discovery programmes.

Novel targets identified will be further validated and characterised by Otsuka as part of its internal development pipeline, with an initial focus on gene therapy applications of identified targets.

Siteseeker looks at different protein shapes to find functionally active peptides that can be targeted by new therapies.

The technology looks at the entire proteome all of the proteins expressed in a live cell environment looking for druggable targets for a chosen disease.

Financial details of the agreement were not disclosed.

Dr Chris Torrance, CEO of PhoreMost, said: This collaboration with Otsuka is further recognition of the power of the Siteseeker approach to drive the identification of novel, druggable targets.

We are particularly excited to be exploring not only small molecule therapeutics but also gene therapy applications of our platform.

PhoreMost was one of two UK-based companies to receive funding from the government-backed agency Innovate UK to receive funding for small molecule research.

The 1 million funding was announced in 2018, and supported PhoreMost and the immune-oncology firm NeoPhore.

The companies won the funding as part of a competition organised by Innovate UK and funded by the UKs Biomedical Catalyst.

PhoreMost is also working with Indias Centre for Chemical Biology and Therapeutics, part of the Institute for Stem Cell Science and Regenerative Medicine (inStem).

The project began in July last year and, with funding from the Indian government, aims to create chemical tools that modulate novel classes of drug targets.

InStem is researching the genetic mechanisms of potency, differentiation and proliferation in human pluripotent cells.

It aims to examine diseases that can potentially be treated by stem cells.

See original here:
UK biotech PhoreMost to work with Otsuka on gene therapy projects - - pharmaphorum

Read More...

Regenerative Medicine Market Business Scenario 2020 | SWOT Analysis by Major Players- Organogenesis Osiris Therapeutics, Vericel Corporation, Stryker…

Tuesday, January 21st, 2020

New Jersey, United States, The report titled, Regenerative Medicine Market has been recently published by Verified Market Research.The report has offered exhaustive analysis of the Regenerative Medicine Market taking into consideration all the crucial aspects like growth factors, constraints, market developments, future prospects, and trends. Market researchers and industry experts have pointed out the key market trends and prospects that may impact the overall Regenerative Medicine Market growth. This will help players to leverage the opportunities to strengthen their position. Also, the report throws light on the important factors that are contributing to the Regenerative Medicine Market growth. Additionally, challenges and impeding factors that could hamper the growth of the Regenerative Medicine Market in the years to come are mentioned in the report.

Global Regenerative Medicine Market was valued at USD 19.10 Billion in 2018 and is expected to witness a growth of 22.72% from 2019-2026 and reach USD 98.10 Billion by 2026.

Request a Sample Copy of this report @https://www.verifiedmarketresearch.com/download-sample/?rid=7157&utm_source=FSA&utm_medium=003

Top 10 Companies in the Global Regenerative Medicine Market Research Report:

Global Regenerative Medicine Market: Competitive Landscape

Competitive landscape of a market explains strategies incorporated by key players of the market. Key developments and shift in management in the recent years by players has been explained through company profiling. This helps readers to understand the trends that will accelerate the growth of market. It also includes investment strategies, marketing strategies, and product development plans adopted by major players of the market. The market forecast will help readers make better investments.

Global Regenerative Medicine Market: Drivers and Restrains

This section of the report discusses various drivers and restrains that have shaped the global market. The detailed study of numerous drivers of the market enable readers to get a clear perspective of the market, which includes market environment, government policies, product innovations, breakthroughs, and market risks.

The research report also points out the myriad opportunities, challenges, and market barriers present in the Global Regenerative Medicine Market. The comprehensive nature of the information will help the reader determine and plan strategies to benefit from. Restrains, challenges, and market barriers also help the reader to understand how the company can prevent itself from facing downfall.

Global Regenerative Medicine Market: Segment Analysis

This section of the report includes segmentation such as application, product type, and end user. These segmentations aid in determining parts of market that will progress more than others. The segmentation analysis provides information about the key elements that are thriving the specific segments better than others. It helps readers to understand strategies to make sound investments. The Global Regenerative Medicine Market is segmented on the basis of product type, applications, and its end users.

Global Regenerative Medicine Market: Regional Analysis

This part of the report includes detailed information of the market in different regions. Each region offers different scope to the market as each region has different government policy and other factors. The regions included in the report are North America, South America, Europe, Asia Pacific, and the Middle East. Information about different region helps the reader to understand global market better.

Ask for Discount @https://www.verifiedmarketresearch.com/ask-for-discount/?rid=7157&utm_source=FSA&utm_medium=003

Table of Content

1 Introduction of Regenerative Medicine Market

1.1 Overview of the Market 1.2 Scope of Report 1.3 Assumptions

2 Executive Summary

3 Research Methodology of Verified Market Research

3.1 Data Mining 3.2 Validation 3.3 Primary Interviews 3.4 List of Data Sources

4 Regenerative Medicine Market Outlook

4.1 Overview 4.2 Market Dynamics 4.2.1 Drivers 4.2.2 Restraints 4.2.3 Opportunities 4.3 Porters Five Force Model 4.4 Value Chain Analysis

5 Regenerative Medicine Market, By Deployment Model

5.1 Overview

6 Regenerative Medicine Market, By Solution

6.1 Overview

7 Regenerative Medicine Market, By Vertical

7.1 Overview

8 Regenerative Medicine Market, By Geography

8.1 Overview 8.2 North America 8.2.1 U.S. 8.2.2 Canada 8.2.3 Mexico 8.3 Europe 8.3.1 Germany 8.3.2 U.K. 8.3.3 France 8.3.4 Rest of Europe 8.4 Asia Pacific 8.4.1 China 8.4.2 Japan 8.4.3 India 8.4.4 Rest of Asia Pacific 8.5 Rest of the World 8.5.1 Latin America 8.5.2 Middle East

9 Regenerative Medicine Market Competitive Landscape

9.1 Overview 9.2 Company Market Ranking 9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview 10.1.2 Financial Performance 10.1.3 Product Outlook 10.1.4 Key Developments

11 Appendix

11.1 Related Research

Request Customization of Report @ https://www.verifiedmarketresearch.com/product/global-regenerative-medicine-market/?utm_source=FSA&utm_medium=003

Highlights of Report

About Us:

Verified market research partners with clients to provide insight into strategic and growth analytics; data that help achieve business goals and targets. Our core values include trust, integrity, and authenticity for our clients.

Analysts with high expertise in data gathering and governance utilize industry techniques to collate and examine data at all stages. Our analysts are trained to combine modern data collection techniques, superior research methodology, subject expertise and years of collective experience to produce informative and accurate research reports.

Contact Us:

Mr. Edwyne Fernandes Call: +1 (650) 781 4080 Email: [emailprotected]

Originally posted here:
Regenerative Medicine Market Business Scenario 2020 | SWOT Analysis by Major Players- Organogenesis Osiris Therapeutics, Vericel Corporation, Stryker...

Read More...

JPM: Biotech, VC execs on where the industry should look beyond cancer – FierceBiotech

Tuesday, January 21st, 2020

SAN FRANCISCOOncology is clearly a major medical and societal issue: a major killer that, while predominately affecting the older population, can strike the young through a mixture of environmental factors or a genetic lottery. Its no wonder we struggle to even call it by its name, preferring just the "big C."

Biopharma has acted accordingly over the years and spent billions (and made many more billions) developing new oncology therapies, with the media and political focus falling on cancer drugs far more acutely than any other area, whether that be over pricing (the current average cost of a new cancer drug in the U.S. is around $100,000), effectiveness/safety or rejection from healthcare gatekeepers, such as the National Institute for Health and Care Excellence in England.

But cancer is only one disease area: Heart disease is the biggest killer in the U.S., yet there are very few new and innovative CV drugs out there, with influenza complications, such as pneumonia, Alzheimers disease, stroke and diabetes complications all leading causes of death in the U.S. There has been a war on cancer, but not a war on stroke.

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

There is also the growing threat of antimicrobial resistance, where decades-old antibiotics are ceasing to work against common forms of bacteria as they evolve; this, coupled with the fact that most life science companies arent working on a next generation of antibiotics (R&D costs are high with little or no ROI), means we could very well be facing a new surge in deaths in the future from once preventable diseases and infections.

At the J.P. Morgan Healthcare Conference in San Francisco this week, we at FierceBiotech wondered what the industry was doing about this and asked a range of life science C-suite execs: What therapeutic areas beyond cancer are most important to the industry now? both in terms of unmet need as well as where there is some real innovation.

Jim Robinson, chief operating officer at Paragon Biosciences, said: I spent 10 years in oncology, so I understand that point. Still, the biggest issue we face today that has to be figured out is Alzheimers. Looking at the aftermath, its scaryits going to be trillions of dollars in 20 short years in terms of the expense treating patients with Alzheimers. In 20 short years, I might be one of those patients!

I think its been a vast wasteland of failure. Im hoping something comes about before Im 70 to allow us to treat it. Whether the industry is willing to shift more resources to pursue treatments or not remains to be seen, especially after the latest failures. I dont know if the industry will shift to Alzheimers or more CNS treatments associated with cognition, but Im hoping.

Oncology good news is when the industry shifted and thousands of drugs moved through development. We see a significant transformation in certain cancers. If the incentive or the approach from a regulatory pathway that shifts incentives to research in Alzheimers, we will find some answers.

The biotechs CEO, Jeff Aronin, who is also CEO of Paragon Capital Partners, echoed this need for answers. I have a focus there with one of our companies, but in general, I would answer a little broader, he explained. Ive been involved in CNS drug development for a very long time and remember the 90s, which they called the decade of the brain, but we really didnt make a lot of advances in neuroscience and psychiatry that we thought we would have.

I think over the next few years is where we are really going to see many medicines approved. We have learned so much more and advancing in many different areas. In neuroscience and psychiatry, I would add theyre also an area of tremendous cost to the healthcare system and we still dont have a lot of great solutions, whether its Alzheimers or any of the neuropsychiatry areas were working in.

BioNTechs Sean Marrett also saw Alzheimers and other neuroscience areas, such as Parkinsons disease, as still major and unmet issues, as well as multiple sclerosis, which has seen great strides but still needs work.

Alzheimers is certainly a major issue, but also one that is more entrenched in the west: We live longer and are therefore more susceptible to diseases associated with aging.

Lyndra Therapeutics CEO Patricia Hurter asked us whether we meant our question in relation to the developed world or the developing world? We asked her two cents on both.

Women in Africa either get pregnant or get HIV, she said starkly. Their economic prospects are horrendous. It means their childrens economic prospects are horrendous. Were working with Gilead on HIV prophylaxis and on an oral birth control. Eventually, when the drugs are potent enough, we could do a once-a-month pill of each. To have them in one capsulethat would be fabulous. That would be transformative for developing countries.

For America, I think so many things like hypertension and diabetes are a chronic epidemic and people are having bad health outcomes [that could be avoided] if they took well proven drugs in an adherent way. Its an adherence issue. Theyre not feeling sick so they dont take the medicine. But in fact, it is still progressing [it, referring to stuff like hypertension, NASH that progressively gets worse without you feeling sick until its advanced].

It leads to unnecessary hospitalizations. If we could combine modern methods of distribution that a poly-pill combination that a person neededonce a week they would take one thing to keep them from progressing.

Karuna Therapeutics CEO Steve Paul also pointed to suicide rates that keep going up, whereas in certain types of cancer and cardiovascular disease theyve started tracking down.

And, finally, Westlake Village Biopartners Managing Partner Sean Harper said: Because there are so many areas of unmet need, its hard to say just one therapeutic area or one modality. Its exciting: the cellular engineering thats going to result in the ability to do regenerative medicine type efforts is I think going to be the next really amazing sort of thing.

With the fact that you can manipulate human cells now the way you can, and make multiple difficult edits to engineer things out of them and so on, that is just a new frontier. There are a lot of settings where you can just imagine what that can do. Its not 100 years away. Its now. Its happening already, people are doing it. I think that, to me, is the most exciting area.

See the original post:
JPM: Biotech, VC execs on where the industry should look beyond cancer - FierceBiotech

Read More...

Global Regenerative Medicine Market expected to Growth at an impressive CAGR during the period of 2020-2025 – Fusion Science Academy

Tuesday, January 21st, 2020

This report focuses on global Vision Sensor status, future forecast, growth opportunity, key market, and key players. The study objectives are to present the Vision Sensor development in the United States, Europe, and China.

In 2018, the global Vision Sensor market size was million US$ and it is expected to reach million US$ by the end of 2025, with a CAGR of during 2019-2025.

The report also summarizes the various types of Vision Sensor market. Factors that influence the market growth of particular product category type and market status for it. A detailed study of the Vision Sensor Market has been done to understand the various applications of the usage and features of the product. Readers looking for scope of growth with respect to product categories can get all the desired information over here, along with supporting figures and facts.

Get Global Vision Sensor sample copy of thisreport https://www.lexisbusinessinsights.com/request-sample-75861

Top Key players: Festo, BALLUFF, BANNERENGINEERINGCORP, CARLOGAVAZZI, COGNEX, DatalogicAutomation, di-soric, HEXAGONMANUFACTURINGINTELLIGENCE, ifmelectronic, ipfelectronicgmbh, LaetusGmbH, LMITechnologies, OMRON, Optekelectronics, Pepperl+FuchsGmbH, SENSOPART, Servo-Robot, SICK, TelemecaniqueSensors, TURCK, VisionComponents, and wenglorsensoricGmbH

Vision Sensor Market: Regional Segment Analysis.

This report provides pin-point analysis for changing competitive dynamics. It offers a forward-looking perspective on different factors driving or limiting market growth. It provides a five-year forecast assessed based on how the Vision Sensor Market is predicted to grow. It helps in understanding the key product segments and their future and helps in making informed business decisions by having complete insights of market and by making an in-depth analysis of market segments.

Key questions answered in the report include:

What will the market size and the growth rate be in 2026?

What are the key factors driving the Global Vision Sensor Market?

What are the key market trends impacting the growth of the Global Vision Sensor Market?

What are the challenges to market growth?

Who are the key vendors in the Global Vision Sensor Market?

What are the market opportunities and threats faced by the vendors in the Global Vision Sensor Market?

Trending factors influencing the market shares of the Americas, APAC, Europe, and MEA.

The report includes six parts, dealing with:

1.) Basic information;

2.) The Asia Vision Sensor Market;

3.) The North American Vision Sensor Market;

4.) The European Vision Sensor Market;

5.) Market entry and investment feasibility;

6.) The reports conclusion.

All the research report is made by using two techniques that are Primary and secondary research. There are various dynamic features of the business, like client need and feedback from the customers. Before (company name) curate any report, it has studied in-depth from all dynamic aspects such as industrial structure, application, classification, and definition.

The report focuses on some very essential points and gives a piece of full information about Revenue, production, price, and market share.

Vision Sensor Market report will enlist all sections and research for every point without showing any indeterminate of the company.

Reasons for Buying this Report

This report provides pin-point analysis for changing competitive dynamics

It provides a forward-looking perspective on different factors driving or restraining the market growth

It provides a six-year forecast assessed based on how the market is predicted to grow

It helps in understanding the key product segments and their future

It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors

It helps in making informed business decisions by having complete insights of market and by making an in-depth analysis of market segments

TABLE OF CONTENT:

1 Report Overview

2 Global Growth Trends

3 Market Share by Key Players

4 Breakdown Data by Type and Application

5 United States

6 Europe

7 China

8 Japan

9 Southeast Asia

10 India

11 Central & South America

12 International Players Profiles

13 Market Forecast 2019-2025

14 Analysts Viewpoints/Conclusions

15 Appendix

Get Global Vision Sensor Complete Brochure @ https://www.lexisbusinessinsights.com/request-sample-75861

About Us:

Statistical surveying reports is a solitary goal for all the business, organization and nation reports. We highlight a huge archive of most recent industry reports, driving and specialty organization profiles, and market measurements discharged by rumored private distributors and open associations. Statistical surveying Store is the far-reaching gathering of market knowledge items and administrations accessible on air. We have statistical surveying reports from a number of driving distributors and update our gathering day by day to furnish our customers with the moment online access to our database. With access to this database, our customers will have the option to profit by master bits of knowledge on worldwide businesses, items, and market patterns

Contact Us:

Lexis Business Insights

Aaryan

(Director- Business Development)

US: +1 210 907 4145

UK: +44 7880 533158

[emailprotected]

http://www.lexisbusinessinsights.com

We are a vibrant market research company which is focused on catering to more and more people day by day. Our research company is one of a few reliable market research report companies in todays date.

See the original post here:
Global Regenerative Medicine Market expected to Growth at an impressive CAGR during the period of 2020-2025 - Fusion Science Academy

Read More...

Sports Medicine Market to Expand at a Healthy Growth Rate in the Coming Years – Press Release – Digital Journal

Tuesday, January 21st, 2020

North America is expected to hold a significant share in the sports medicine market during the forecast period

This press release was orginally distributed by SBWire

Northrook, IL -- (SBWIRE) -- 01/20/2020 -- Growth in the sports medicine analysis market can be attributed to factors such as the increasing incidence of sports injuries, continuous influx of new products & treatment modalities, and developments in the field of regenerative medicine. On the other hand, the high cost of implants and other devices and the dearth of skilled professionals are expected to limit market growth to a certain extent during the forecast period.

What the Market Looks Like?

Predicted to grow at a CAGR of 6.5% during the forecast period, the global sports medicine market is estimated to reach USD 9.1 Billion by the end of 2024. Factors such as the rising popularity of sports and physical activity, increasing awareness regarding the prevention & treatment of sports injuries, and growing investments in sports medicine are driving the North American market.

On the basis of products, the sports medicine market is segmented into body reconstruction products (fracture & ligament repair products, arthroscopy devices, implants, prosthetics, orthobiologics), body support & recovery products (braces & support, physiotherapy equipment, and compression clothing), and accessories. The body support & recovery products segment is expected to witness the fastest growth during the forecast period. Products such as braces, supports, and physiotherapy equipment are required before and after procedures involving reconstruction. Thus, the demand for these devices is growing due to the increasing number of sports injuries globally.

Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=751

Sports medicine is widely used for the prevention of sports injuries as well as for the cure, recovery, and rehabilitation of athletes. The sports medicine applications market is segmented into knee injuries, shoulder injuries, foot & ankle, elbow & wrist, back & spine, hip & groin, and other injuries. The knee injuries segment held the largest share of the market in 2018, a trend that is expected to continue during the forecast period. The large share of this segment can be attributed to the fact that a large number of knee injuries are recorded across major sports, globally, accounting for approximately 40% of all injuries due to sports.

What Drives the Market?

The growth of the global market for sports medicine is primarily influenced by the following factors:

- Increasing Incidence of Sports Injuries - Continuous Influx of New Products and Treatment Modalities - Developments in the Field of Regenerative Medicine

Request Research Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=751

Geographical growth scenario of Sports Medicine Market:

Geographically, North America is expected to dominate the global sports medicine market in 2018, while the Asia Pacific region is expected to register the highest CAGR during the forecast period.

The high growth in this region can be attributed to the growth of the sports industry and overall participation in sports. Sporting events such as the 2008 Beijing Olympics, 2018 Winter Olympics in Korea, and the upcoming 2020 Summer Olympics in Japan have increased the level of interest in sports in Asia.

Leading market players and strategies adopted:

The major players operating in the sports medicine market include Arthrex, Inc (US), Smith & Nephew plc (UK), and Stryker Corporation (US). Other players involved in this market include Breg Inc. (US), DJO Global, Inc. (US), Mueller Sports, Inc. (US), Wright Medical Group N.V. (US), Medtronic (Ireland), RTI Surgical (US), Performance Health International Limited (US), KARL STORZ (Germany), and Bauerfeind AG (US).

Request Bundle Reports: https://www.marketsandmarkets.com/RequestBundleReport.asp?id=751

About MarketsandMarketsMarketsandMarkets provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:

Mr. Shelly SinghMarketsandMarkets INC.630 Dundee RoadSuite 430Northbrook, IL 60062USA : 1-888-600-6441sales@marketsandmarkets.com

For more information on this press release visit: http://www.sbwire.com/press-releases/sports-medicine-market-to-expand-at-a-healthy-growth-rate-in-the-coming-years-1271600.htm

Original post:
Sports Medicine Market to Expand at a Healthy Growth Rate in the Coming Years - Press Release - Digital Journal

Read More...

Stem Cell Assay Market to Expand at a Healthy CAGR of XX% Between and 2017 2025 Dagoretti News – Dagoretti News

Tuesday, January 21st, 2020

In 2019, the market size of Stem Cell Assay Market is million US$ and it will reach million US$ in 2025, growing at a CAGR of from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.

In this report, 2019 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Stem Cell Assay .

This report studies the global market size of Stem Cell Assay , especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).

Request Sample Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=40&source=atm

This study presents the Stem Cell Assay Market production, revenue, market share and growth rate for each key company, and also covers the breakdown data (production, consumption, revenue and market share) by regions, type and applications. Stem Cell Assay history breakdown data from 2014 to 2019, and forecast to 2025.

For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

In global Stem Cell Assay market, the following companies are covered:

growth drivers and lists down the major restraints. Additionally, the report gauges the effect of Porters five forces on the overall stem cell assay market.

Global Stem Cell Assay Market: Key Market Segments

For the purpose of the study, the report segments the global stem cell assay market based on various parameters. For instance, in terms of assay type, the market can be segmented into isolation and purification, viability, cell identification, differentiation, proliferation, apoptosis, and function. By kit, the market can be bifurcated into human embryonic stem cell kits and adult stem cell kits. Based on instruments, flow cytometer, cell imaging systems, automated cell counter, and micro electrode arrays could be the key market segments.

In terms of application, the market can be segmented into drug discovery and development, clinical research, and regenerative medicine and therapy. The growth witnessed across the aforementioned application segments will be influenced by the increasing incidence of chronic ailments which will translate into the rising demand for regenerative medicines. Finally, based on end users, research institutes and industry research constitute the key market segments.

The report includes a detailed assessment of the various factors influencing the markets expansion across its key segments. The ones holding the most lucrative prospects are analyzed, and the factors restraining its trajectory across key segments are also discussed at length.

Global Stem Cell Assay Market: Regional Analysis

Regionally, the market is expected to witness heightened demand in the developed countries across Europe and North America. The increasing incidence of chronic ailments and the subsequently expanding patient population are the chief drivers of the stem cell assay market in North America. Besides this, the market is also expected to witness lucrative opportunities in Asia Pacific and Rest of the World.

Global Stem Cell Assay Market: Vendor Landscape

A major inclusion in the report is the detailed assessment of the markets vendor landscape. For the purpose of the study the report therefore profiles some of the leading players having influence on the overall market dynamics. It also conducts SWOT analysis to study the strengths and weaknesses of the companies profiled and identify threats and opportunities that these enterprises are forecast to witness over the course of the reports forecast period.

Some of the most prominent enterprises operating in the global stem cell assay market are Bio-Rad Laboratories, Inc (U.S.), Thermo Fisher Scientific Inc. (U.S.), GE Healthcare (U.K.), Hemogenix Inc. (U.S.), Promega Corporation (U.S.), Bio-Techne Corporation (U.S.), Merck KGaA (Germany), STEMCELL Technologies Inc. (CA), Cell Biolabs, Inc. (U.S.), and Cellular Dynamics International, Inc. (U.S.).

Request For Discount On This Report @ https://www.tmrresearch.com/sample/sample?flag=D&rep_id=40&source=atm

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Stem Cell Assay product scope, market overview, market opportunities, market driving force and market risks.

Chapter 2, to profile the top manufacturers of Stem Cell Assay , with price, sales, revenue and global market share of Stem Cell Assay in 2017 and 2019.

Chapter 3, the Stem Cell Assay competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Stem Cell Assay breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2019.

Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2019.

Customize This Report @ https://www.tmrresearch.com/sample/sample?flag=CR&rep_id=40&source=atm

Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2019.

Chapter 12, Stem Cell Assay market forecast, by regions, type and application, with sales and revenue, from 2019 to 2024.

Chapter 13, 14 and 15, to describe Stem Cell Assay sales channel, distributors, customers, research findings and conclusion, appendix and data source.

Go here to see the original:
Stem Cell Assay Market to Expand at a Healthy CAGR of XX% Between and 2017 2025 Dagoretti News - Dagoretti News

Read More...

Amnion of Florida Announces Greater Geographic Reach for Their Regenerative Health Services by Partnering With Care First Medical Group – Business…

Friday, January 3rd, 2020

ORLANDO, Fla.--(BUSINESS WIRE)--Amnion of Florida, a leading provider of alternative medicine utilizing cryopreserved placental cell allograft for advanced bioactive facial rejuvenation, is pleased to announce a partnership to enhance patient outcomes for joint pain and anti-aging therapies.

Amnion announces a partnership with Care First Medical Group, Inc. to improve patients experience with managed medical care and provide non-pharmaceutical solutions for joint repair/pain management and anti-aging. The goals of the collaboration are to provide alternatives to medical care and to help patients seeking to eliminate chronic joint pain, look younger, and take a more active role in mapping their medical care to avoid illness in the future.

Sabriya Rogers, President of Care First, states, Our Board-Certified primary care providers specialize in managed health, thus patients can take a proactive approach in deciding the course of their care, which yields a lower cost to patients, while keeping families together, and maintaining a high degree of medical care.

The partnership will provide more location options for patients. With offices throughout greater Orlando, Sanford, Leesburg, Palm Coast, and Longwood, patients will find a location nearby that fits busy schedules.

Our team of medical professionals and aestheticians at Amnion are excited to partner with Care First to provide enhanced medical care and rejuvenation services at our partnership locations, said Eusebio Coterillo, President of Amnion.

In a constantly changing field, Amnion of Florida, under the guidance of an on-site medical staff, provides the highest level of quality products and procedures in regenerative medicine. They offer cutting edge treatments that are shown to be effective, use FDA cleared or registered products, and are widely published and peer endorsed. The collaboration with Care First will bring added benefits such as managed care, urgent care, and programmed care for long term issues such as high blood pressure, diabetes, high cholesterol, asthma, and allergies in a full-service clinical setting.

More about Amnion of Florida

Amnion of Florida, based in Central Florida, is a leading provider of alternative medicine using cryopreserved placental cell transplants or allografts, processed from donated cellular birth tissue, which are natural alternatives to autologous regenerative medicine products. The primary function of our allogeneic regenerative treatments is to promote soft tissue joint/skin repair and regeneration mediated by growth factors and cells naturally found in placental tissue. These treatments have shown safety and efficacy in treating a variety of ailments including osteoarthritis, chronic ulcerative wounds, joint pain, skin rejuvenation, hair restoration, urinary incontinence, and ED. Learn more at http://www.amnion.us.

More about Care First Medical Group, Inc.

Care First, based in Central Florida, is focused on providing affordable healthcare for primary and urgent care needs through prevention, patient education, with the personal touch to improve communication with the patient, and patients overall health. Our vision is to transform the health care experience through a culture of caring, quality, safety, service, innovation, and excellence. Our goal is to be recognized by employees, physicians, patients and families, volunteers, and the community as a company that delivers results through our proactive approach to medicine. Learn more or schedule an appointment at (407) 449-0632.

Read this article:
Amnion of Florida Announces Greater Geographic Reach for Their Regenerative Health Services by Partnering With Care First Medical Group - Business...

Read More...

BrainStorm Cell Therapeutics Wins 2020 ‘Buzz of BIO’ Award for ALS Investigational Therapy – ALS News Today

Friday, January 3rd, 2020

For its promising investigational therapeutic approach to neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), BrainStorm Cell Therapeutics is theBuzz of BIO 2020 winnerin the Public Therapeutic Biotech category.

The Buzz of BIO contest identifies U.S. companies with groundbreaking, early-stage potential to improve lives. The event also is anopportunity to make investor connections that could take products to the next phase.

Ten biotechnology companies are nominated in each of the three categories ofBuzz of BIO: Public Therapeutic Biotech, Private Therapeutic Biotech, and Diagnostics and Beyond. In the Public Therapeutic Biotech category that BrainStorm won, nominated companies must be actively developing a publicly traded human treatment intended for review by theU.S. Food and Drug Administration (FDA).

As a developer of autologous cellular therapies treatments that use a patients own cells and tissues for debilitating neurodegenerative diseases, BrainStorm is now testing its NurOwn therapy for safety and effectiveness. The treatment involves extracting, from human bone, marrow-derived mesenchymal stem cells (MSCs), which are capable of differentiating into other cell types. The MSCs are then matured into a specific cell type that produces neurotrophic factors compounds that promote nervous tissue growth and survival. They are then reintroduced to the body via injection into muscles and/or the spinal canal.

Backed by a California Institute for Regenerative Medicine grant, Brainstorm has fully enrolledits randomized, double-blind, placebo-controlled Phase 3 clinical trial (NCT03280056) at six U.S. sites in California, Massachusetts, and Minnesota. Some 200 ALS patients are participating. A secondary safety analysis by the trials independent Data Safety Monitoring Board (DSMB) revealed no new concerns. Every two months, study subjects will be given three injections into the spinal canal of either NurOwn or placebo.

The trial is expected to conclude late this year. Results will be announced shortly afterward.

In a Phase 2 study (NCT02017912), which included individuals with rapidly progressing ALS, NurOwn demonstrated a positive safety profile as well as prospective efficacy.

The use of autologous MSC cells to potentially treat ALS was given orphan drug status by both the FDA and the European Medicines Agency.

Thanks to everyone who voted for BrainStorm during the Buzz of BIO competition,Chaim Lebovits, BrainStorm president and CEO, said in a press release. The entire management team at BrainStorm was very pleased with the results of this competition, and we look forward to presenting to an audience of accredited investors who may benefit from the companys story. We thank the BIO[Biotechnology Innovation Organization] team for singling out BrainStorms NurOwn as a key technology with the potential to improve lives.

As a contest winner, BrainStorm is invited to givea presentation at theBio CEO & Investor Conference, to be held Feb. 1011 in New York City, along with exposure to multiple industry elites and potential investors.

NurOwn cells also are being tested in a Phase 2 clinical study (NCT03799718) in patients with progressive multiple sclerosis.

Mary M. Chapman began her professional career at United Press International, running both print and broadcast desks. She then became a Michigan correspondent for what is now Bloomberg BNA, where she mainly covered the automotive industry plus legal, tax and regulatory issues. A member of the Automotive Press Association and one of a relatively small number of women on the car beat, Chapman has discussed the automotive industry multiple times of National Public Radio, and in 2014 was selected as an honorary judge at the prestigious Cobble Beach Concours dElegance. She has written for numerous national outlets including Time, People, Al-Jazeera America, Fortune, Daily Beast, MSN.com, Newsweek, The Detroit News and Detroit Free Press. The winner of the Society of Professional Journalists award for outstanding reporting, Chapman has had dozens of articles in The New York Times, including two on the coveted front page. She has completed a manuscript about centenarian car enthusiast Margaret Dunning, titled Belle of the Concours.

Total Posts: 6

Ins holds a PhD in Biomedical Sciences from the University of Lisbon, Portugal, where she specialized in blood vessel biology, blood stem cells, and cancer. Before that, she studied Cell and Molecular Biology at Universidade Nova de Lisboa and worked as a research fellow at Faculdade de Cincias e Tecnologias and Instituto Gulbenkian de Cincia. Ins currently works as a Managing Science Editor, striving to deliver the latest scientific advances to patient communities in a clear and accurate manner.

Link:
BrainStorm Cell Therapeutics Wins 2020 'Buzz of BIO' Award for ALS Investigational Therapy - ALS News Today

Read More...

Rexgenero CEO Talks Importance of Dialogue in Cell Therapy Conversations – Xconomy

Friday, January 3rd, 2020

XconomyNational

Cell and gene therapies are becoming more mainstream, but an essential aspect of the drug development process is talking with clinicians about how it would fit into their practice, according to Joe Dupere, CEO of UK-based regenerative medicine company Rexgenero.

Rexgenero is advancing an experimental cell therapy for critical limb ischemia, a chronic condition that causes severe burning pain in the feet or toes as a result of blocked arteries in the lower limbs. Patients often get ulcers that can lead to amputation of the affected limb.

The company, headquartered in London, has R&D and manufacturing operations in Spain. Dupere talked with journalist Mike Ward at BIO-Europe 2019 in Hamburg, Germany, about the companys progress and plans.

Theres a lot of dialogue with the physicians and the surgeons that we cooperate with in our trial so they understand our product, its place in the treatment of this disease, and understanding when they can bring in patients and potential benefits, Dupere said.

When it comes to involving clinicians in its studies, the earlier, the better, Dupere said he learned as the company advanced its investigational treatments.

We live and breathe our design of our study, but surgeons are coming into this new, and to really understand how it works and really assist them in that journey with us so that they can bring patients in, we make it as easy as possible for them to participate, he said.

Although the type of treatment isnt as unusual as it once was, detailing how Rexgeneros cell therapies could impact how care is currently provided is essential to getting buy-in from the physicians who would use it, he said.

The challenge for us is to really demonstrate the superiority, in terms of the efficacy that we can show, and how that fits in with their practice, he said. Thats also marrying what they do already, which is a series of surgical and in endovascular procedures, [with] where the cell therapies can come in and really turbocharge that and have a really substantial impact on their patients.

As Rexgenero focuses on its Phase 3 trials, its priorities have included thinking through how the product would be used if it were to make it to commercialization.

Theres a whole range of other activities that we need to focus on as we get nearer to the market, he said.One is scaling up the manufacture, so thats a truly commercial manufacturing process that can really deliver the product to as many patients as possible. The second is really understanding how this would be used in practice, so from a commercial perspective, how would you sell this product, how would you position it with the physicians, and how would you get the surgeons to understand where this treatment would work in their general practice.

Duprere said the company also aims to expand into supplementary indications and establish a presence in the US.

Talking with investors as BIO-Europe, Duprere said he noticed more of an appreciation for biotechs that are doing cell therapy work outside of immune-oncology, a hot area for life sciences financings.

I think when you talk about [strategic investors], the core value proposition of the disease and the treatment of the disease and the unmet need of the disease has been understood from the beginning, but utilization of a cell therapy to be able to address that market is something that theyre getting much more familiar with, certainly around things like the manufacture, some of the regulation thats specific to cell therapies, and also the commercial path, when youre dealing with a curative product where you give a single dose of the product and you expect a cure for the patient.

Sarah de Crescenzo is an Xconomy editor based in San Diego. You can reach her at sdecrescenzo@xconomy.com.

View original post here:
Rexgenero CEO Talks Importance of Dialogue in Cell Therapy Conversations - Xconomy

Read More...

Page 29«..1020..28293031..4050..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick